An approach to the treatment of pediatric myocarditis

Pediatric Drugs

Volumn 4, Issue 10, 2002, Pages 637-647

  Levi, Daniel ^a   Alejos, Juan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AMIODARONE; ANTIVIRUS AGENT; CAPTOPRIL; CHLOROTHIAZIDE; DIGOXIN; DIPYRIDAMOLE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENALAPRIL; ENALAPRILAT; ETACRYNIC ACID; FUROSEMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; IRON; LIDOCAINE; LOBENZARIT; MANNITOL; MILRINONE; NITROPRUSSIDE SODIUM; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS; UNINDEXED DRUG; VASODILATOR AGENT; VIRUS VACCINE; WARFARIN;

ADOLESCENT; CHILD; CLINICAL TRIAL; DIURETIC THERAPY; DRUG EFFECT; DRUG EFFICACY; EXTRACORPOREAL OXYGENATION; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MYOCARDITIS; NEWBORN; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; CHILD; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNOTHERAPY; MYOCARDITIS;

EID: 0036395137     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204100-00002     Document Type: Review

References (91)

1. Daubeney P. Nugent A, Davis AM, et al. Incidence and outcome of childhood cardiomyopathy in Australia: results of a ten year population based study [abstract]. J Am Coll Cardiol 1999; 33 Suppl. A: 496A
2. Nakagawa M, Sato A, Okagawa H, et al. Detection and evaluation of asymptomatic myocarditis in school children. Chest 1999; 116: 340-5
3. Press S, Lipkind RS. Acute myocarditis in infants: initial presentation. Clin Pediatr 1990; 29: 73-6
4. Kline IK, Kline TS, Saphir O. Myocarditis in senescence. Am Heart J 1963; 65: 446-57
5. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343 (19): 1388-98
6. Noren GR, Staley NA, Brandt GM, et al. Occurrence of myocarditis in sudden death in children. J Forensic Sci 1977; 22: 188-96
7. Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis: rapid diagnosis by PCR in children. Circulation 1994; 90: 330-9
8. Hirschman ZS, Hammer SG. Coxsackie virus myopericarditis: a microbiological and clinical review. Am J Cardiol 1974; 34: 224-32
9. Proby CM, Hackett S, Gupta S, et al. Acute myopericarditis in influenza A infection. Q J Med 1986; 60: 887-92
10. Schonian U, Crombach M, Maser S, et al. Cytomegalovirus associated heart muscle disease. Eur Heart J 1995; 16 Suppl. O: 46-9
11. Lowry PJ, Thompson RA, Littler WA. Humoral immunity in cardiomyopathy. Br Heart J 1983; 50: 390-4
12. Schwonengerdt KO. Ni J, Denfield SW, et al. Parvovirus B19 as a cause of myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction (PCR). Circulation 1997; 96: 3549-54
13. Okabe M, Fukuda K, Arakawa K, et al. Chronic variant myocarditis associated with hepatits C virus infection. Circulation 1997; 97: 22-4
14. Ainger LE. Lawyer NG, Fitch CW. Neonatal rubella myocarditis. Br Heart J 1966; 28: 691-7
15. Lorber A, Zonis A, Maisuls E, et al. The scale of myocardial involvement in varicella myocarditis. Int J Cardiol 1988; 20: 257-62
16. Chaundry S. Jaski BE. Fulminant mumps myocarditis. Ann Intern Med 1989; 110: 569-70
17. Noorullah A, Jiyuan N, Stromberg D, et al. Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis. Circulation 1999; 99 (15): 2011-8
18. Fishman W, Kraus ME, Zabkar J, et al. Infectious mononucleosis and fatal myocarditis. Chest 1977; 72: 535-8
19. Barbaro G, Di Lorenzo G, Grisorio B, et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N Engl J Med 1998; 339: 1093-9
20. Bowles N, Kearny D, Perez-Atayde A, et al. The detection of viral genomes by the polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. J Am Coll Cardiol 1999; 34 (3): 857-65
21. McManus BM, Chow LH, Wilson JE, et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 1993; 68 (2): 159-69
22. Kishimoto C, Crumpacker CS, Abelmann WH, et al. Ribavirin treatment of coxsackie virus B3 myocarditis with analysis of lymphocyte subsets. J Am Coll Cardiol 1988; 12: 1334-41
23. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Circulation 1999; 99: 1091-100
24. Lawson CM, O'Donoghue H, Reed WD. Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis. Immunology 1992; 75 (3): 513-9
25. Godeny EK, Gauntt CJ. Murine natural killer cells limit coxsackie B3 replication. J Immunol 1987; 139: 913-8
26. Lane JR. Neumann DA, Lafond-Walker A, et al. Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 1993; 151 (3): 1682-90
27. Wong CY. Woodruff JJ, Woodruff JF. Characterization of cytotoxic T lymphocytes during coxsackie B-3 infection. II: characterization of effector cells and demonstration of cytotoxicity against viral infected cells. J Immunol 1997; 118: 165-9
28. Henke A, Huber S, Stelzner A, et al. The role of CD8+ T lymphocytes in coxsackie B3-induced viral myocarditis. J Virol 1995; 69 (11): 6720-8
29. Opavsky MA, Penninger J. Aitken K, et al. Susceptibility to myocarditis is dependent on the response of alpha-beta lymphocytes to coxsackie infection. Circ Res 1999; 85: 551-8
30. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994; 89 (2): 846-51
31. Nishio R, Matsumori A, Shioi T, et al. Treatment of experimental viral myocarditis with interleukin- 10. Circulation 1999; 100: 1102-8
32. Klingel K, Stephan S, Sauter M, et al. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol 1996; 70 (12): 8888-95
33. Drucker NA, Newburger JW. Viral myocarditis: diagnosis and management. Adv Pediatr 1997; 4: 141-69
34. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1: 3-14
35. Lieberman E, Hutchins G, Herskowitz A, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18 (7): 1617-26
36. Basso C, Corrado D, Rossi L, et al. Ventricular pre-excitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation 2001; 103: 269-75
37. Friedrich MG, Strohm O. Schulz-Menger J. et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97 (18): 1802-9
38. Koide H, Kitaura Y, Deguchi H, et al. Viral genomic detection in the hearts of C3H/He mice with experimental coxsackievirus B3 myocarditis by gene amplification using the polymerase chain reaction. Jpn Circ J 1992; 56 (2): 148-56
39. Wee L. Liu P, Penn L, et al. Persistence of viral genome into late stages of murine myocarditis detected by polymerase chain reaction. Circulation 1992; 86 (5): 1605-14
40. Nicholson F, Ajetunmobi JF, Li M, et al. Molecular detection and serotypic analysis of enterovirus RNA in archival specimens from patients with acute myocarditis. Br Heart J 1995; 74 (5): 522-7
41. Tracy S, Wiegand V, McManus B, et al. Molecular approaches to enteroviral diagnosis in idiopathic cardiomypathy and myocarditis. J Am Coll Cardiol 1990; 15: 1688-94
42. Kandolf R, Ameis D, Kirschner P, et al. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987; 84: 6272-6
43. Okada I, Matsumori A, Kawai C, et al. The viral genome in experimental murine coxsackievirus B3 myocarditis: a northern blotting analysis. J Mol Cell Cardiol 1990; 22 (9): 999-1008
44. Li W, Crombach M, Schonian U, et al. Detection of cytomegalovirus genome by in situ hybridization in paraffin embedded endomyocardial biopsy specimens of viral myocarditis. Chin Med J (Engl) 1994; 107 (12): 888-91
45. Taketomo C, Hurlburt JH, Kraus DM. Pediatric dosage handbook. 7th ed. Hudson (OH): Lexi-Comp Inc, 2000
46. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993; 22 (4 Suppl. A): A99-105
47. Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 1999; 63: 934-40
48. Dong R, Liu P, Wee L, et al. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin invest 1992; 90: 2022-30
49. Gunthard J, Stocker F, Bolz D, et al. Dilated cardiomyopathy and thromboembolism. Eur J Pediatr 1997; 156: 3-6
50. Kupferschmid C, Schmaltz A, Tacke E, et al. Left ventricular thrombi in three children with dilated cardiomyopathy: diagnostic procedure and clinical course. Pediatr Cardiol 1984; 5 (1): 65-9
51. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-7
52. Takada H, Kishimoto C, Hiraoka Y, et al. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackie B3 model. Circulation 1995; 92: 1604-11
53. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95 (11): 2476-9
54. McNamara DM, Starling RC. Dec GW, et al. Intervention in myocarditis and acute cardiomyopathy with immune globulin: results from the randomized placebo controlled IMAC trial [abstract]. Circulation 1999; 100 Suppl. 1: 1-21
55. Sato Y, Maruyama S, Kawai C, et al. Effect of immunostimulant therapy on acute viral myocarditis in an animal model. Am Heart J 1992; 124 (2): 428-34
56. Yokoyama T, Kanda T, Suzuki T, et al. Effects of lobenzarit on murine acute viral myocarditis. Cardiovasc Drugs Ther 1992; 6 (4): 403-7
57. Takada H, Kishimoto C, Kuroki Y, et al. Effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis. Heart Vessels 1993; 8 (2): 59-66
58. Matoba Y, Matsumori A, Okada I, et al. The effect of cyclosporine on the immunopathogenesis of viral myocarditis in mice. Jpn Circ J 1991; 55 (4): 407-16
59. Matsumori A, Kawai C. Immunomodulating therapy in experimental myocarditis. Springer Semin Immunopathol 1989; 11: 77-88
60. Hahn EA, Hartz VL, Moon TE, et al. The myocarditis treatment trial: design, methods and patient enrollment. Eur Heart J 1995; 16: 162-7
61. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressant therapy for myocarditis. N Engl J Med 1995; 333 (5): 269-75
62. Herzum M, Huber SA, Weller R, et al. Treatment of experimental murine coxsackie B3 myocarditis. Eur Heart J 1991; 12 Suppl. D: 200-2
63. Maisch B, Schonian U, Hengstenberg C, et al. Immunosuppressant therapy for autoreactive myocarditis: results from a controlled trial. Postgrad Med J 1994; 70 Suppl. 1: 29-34
64. Maisch B, Herzum M, Hufnagel G, et al. Immunosuppresive and immunomodulatory therapy for myocarditis. Curr Opin Cardiol 1996; 11: 310-24
65. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis: natural history and treatment. N Engl J Med 1997; 336: 1860-6
66. Ahdoot J, Galindo A, Alejos JC, et al. Use of OKT3 for acute myocarditis in infants and children. J Heart Lung Transplant 2000; 19: 1118-21
67. Daley AJ, Isaacs D, Dwyer DE, et al. A cluster of neonatal coxsackie B meningitis and myocarditis. J Paediatr Child Health 1998; 34 (2): 196-8
68. Herzum M, Weller R, Pankuweit S, et al. Treatment of murine coxsackie virus B3 myocarditis with antiviral monoclonal antibodies [abstract]. Circulation 1991; 84 Suppl.: 634A
69. Pauksen K, Ilback NG, Friman G, et al. Therapy of coxsackie virus B3-induced myocarditis with WIN 54954 in different formulations. Scand J Infect Dis 1993; 88: 125-30
70. Rotbart HA. Antiviral therapy for enteroviral infections. Pediatr Infect Dis J 1999; 18 (7): 632-3
71. Matsumori A, Wang H, Abelmann WH, et al. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation 1985; 71: 834-9
72. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 1992; 89 (1): 314-8
73. Fohlman J, Pauksen K, Morein B, et al. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis 1993; 88: 103-8
74. Grumbach IM, Heim A, Ping-Akerblom I, et al. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol 1999; 54: 83-8
75. Morrow RW, Naftel D, Chinnock R, et al. Outcomes of listing for heart transplantation in infants younger than six months: predictors of death and interval to transplant. J Heart Lung Transplant 1997; 16 (12): 1255-66
76. Farrar DJ, Hill JD. Recovery of major organ function in patients awaiting heart transplantation with thoratec ventricular assist devices. J Heart Lung Transplant 1994; 13 (6): 1125-32
77. Levi D, Marelli D, Plunkett M, et al. The complementary use of ECMO and VADs to support pediatric cardiomyopathy patients listed for transplantation. J Heart Lung Transplant 2002; 21 (7): 760-70
78. Duncan BW, Hraska VH, Jonas R, et al. Mechanical circulatory support in children with cardiac disease. J Thorac Cardiovasc Surg 1999; 117 (3): 529-42
79. Hetzer R, Matthias L, Evgenij V, et al. Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Ann Thorac Surg 1998; 66: 1498-506
80. Morrow RW. Cardiomyopathy and heart transplantation in children. Curr Opin Cardiol 2000; 15: 216-23
81. Lowenstein CJ, Hill SL, Lafond-Walker A, et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 1996; 97 (8): 1837-43
82. Shiota K, Sasayama S. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis: a possible mechanism through inhibition of nitric oxide production. Circulation 1997; 95 (1): 245-51
83. Ishiyama S, Hiroe M, Nishikawa T, et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 1997; 95: 489-96
84. Lane JR, Neumann DA, Lafond-Walker A, et al. Interleukin 1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 1992; 175 (4): 1123-9
85. Heim A, Stille-Siegener M, Kandolf R, et al. Enterovirus-induced myocarditis: hemodynamic deterioration with immunosuppressive therapy and successful application of interferon-alpha. Clin Cardiol 1994; 17 (10): 563-5
86. Huber SA, Polger J, Schultheiss P. et al. Augmentation of coxsackie B3 infections in mice by exogenous administration of Il-1 and Il-2. J Virol 1994; 68:195-206
87. Kishimoto C, Kuroki Y, Hiraoka Y, et al. Cytokine and murine coxsackie B3 myocarditis: Il-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation 1994; 89: 2836-42
88. Miric M, Vasiljevic J, Bolic M, et al. Long-term follow up of patients with dilated heart muscle disease treated with human leukocytic interferon alpha or thymic hormones. Heart 1996; 75: 596-601
89. Nanda T, Nagaoka H, Kaneko K, et al. Synergistic effects of tacrolimus and human interferon-alpha A/D in murine myocarditis. J Pharmacol Exp Ther 1995; 274 (1): 487-93
90. Matsumori A, Ono K, Nishio R, et al. Amiodarone inhibits the production of tumor necrosis factor-α by human mononuclear cells. Circulation 1997; 96: 1386-9
91. Bruns L, Chrisant MK, Lamour J, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001; 138: 505-11